Prognostic value of sepsis-induced coagulation abnormalities: an early assessment in the emergency department.


Journal

Internal and emergency medicine
ISSN: 1970-9366
Titre abrégé: Intern Emerg Med
Pays: Italy
ID NLM: 101263418

Informations de publication

Date de publication:
04 2019
Historique:
received: 05 02 2018
accepted: 20 11 2018
pubmed: 12 12 2018
medline: 30 1 2020
entrez: 12 12 2018
Statut: ppublish

Résumé

To evaluate if the assessment of coagulation abnormalities at ED admission could improve prognostic assessment of septic patients. This report utilizes a portion of the data collected in a prospective study, with the aim to identify reliable biomarkers for an early sepsis diagnosis. In the period November 2011-December 2016, we enrolled 268 patients, admitted to our High-Dependency Unit with a diagnosis severe sepsis/septic shock. Study-related blood samplings were performed at ED-HDU admission (T0), after 6 h (T6) and 24 h (T24): D-dimer, thrombin-antithrombin complex (TAT) and prothrombin fragment F1 + 2 levels were analyzed. The primary end-points were day-7 and in-hospital mortality. Day-7 mortality rate was 16%. D-dimer (T0: 4661 ± 4562 µg/ml vs 3190 ± 7188 µg/ml; T6: 4498 ± 4931 µg/ml vs 2822 ± 5623 µg/ml; T24 2905 ± 2823 µg/ml vs 2465 ± 4988 µg/ml, all p < 0.05) and TAT levels (T0 29 ± 45 vs 22 ± 83; T6 21 ± 22 vs 15 ± 35; T24 16 ± 19 vs 13 ± 30, all p < 0.05) were higher among non-survivors compared to survivors. We defined an abnormal coagulation activation (COAG+) as D-dimer > 500 µg/ml and TAT > 8 ng/ml (for both, twice the upper normal value). Compared to COAG-, COAG+ patients showed higher lactate levels at the earliest evaluations (T0: 3.3 ± 2.7 vs 2.5 ± 2.3, p = 0.041; T6: 2.8 ± 3.4 vs 1.8 ± 1.6, p = 0.015); SOFA score was higher after 24 h (T24: 6.7 ± 3.1 vs 5.4 ± 2.9, p = 0.008). At T0, COAG+ patients showed a higher day-7 mortality rate (HR 2.64; 95% CI 1.14-6.11, p = 0.023), after adjustment for SOFA score and lactate level. Presence of abnormal coagulation at ED admission shows an independent association with an increased short-term mortality rate.

Identifiants

pubmed: 30535649
doi: 10.1007/s11739-018-1990-z
pii: 10.1007/s11739-018-1990-z
doi:

Substances chimiques

Biomarkers 0
Fibrin Fibrinogen Degradation Products 0
antithrombin III-protease complex 0
fibrin fragment D 0
Antithrombin III 9000-94-6
Peptide Hydrolases EC 3.4.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

459-466

Références

Semin Thromb Hemost. 2015 Feb;41(1):9-15
pubmed: 25590524
Crit Care. 2004 Apr;8(2):R82-90
pubmed: 15025782
Crit Care Med. 2003 Apr;31(4):1250-6
pubmed: 12682500
Crit Care Med. 2009 May;37(5):1649-54
pubmed: 19325482
Am J Emerg Med. 2016 Sep;34(9):1788-93
pubmed: 27321936
Shock. 2005 Jun;23(6):488-93
pubmed: 15897799
Thromb Res. 2017 Jan;149:38-44
pubmed: 27886531
Crit Care Med. 2004 Dec;32(12):2416-21
pubmed: 15599145
Eur J Emerg Med. 2014 Aug;21(4):254-9
pubmed: 23970100
Crit Care. 2013 Apr 11;17(2):R68
pubmed: 23577792
Eur J Intern Med. 2015 Dec;26(10):782-6
pubmed: 26586287
Acta Anaesthesiol Scand. 2017 Aug;61(7):790-796
pubmed: 28681428
JAMA. 2001 Oct 10;286(14):1754-8
pubmed: 11594901
J Innate Immun. 2018;10(5-6):502-514
pubmed: 29763894
Br J Haematol. 2006 Oct;135(2):220-7
pubmed: 17010048
Crit Care Med. 2006 Feb;34(2):314-20; quiz 328
pubmed: 16424708
Blood Coagul Fibrinolysis. 2017 Mar;28(2):163-170
pubmed: 27254441
Crit Care. 2014 Jan 13;18(1):R13
pubmed: 24410881
Intern Emerg Med. 2018 Apr;13(3):405-412
pubmed: 28188577
Crit Care. 2010;14(5):R182
pubmed: 20942957

Auteurs

Francesca Innocenti (F)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria Careggi, Lg. Brambilla 3, 50134, Florence, Italy. innocenti.fra66@gmail.com.

Anna Maria Gori (AM)

Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy.

Betti Giusti (B)

Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy.

Camilla Tozzi (C)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria Careggi, Lg. Brambilla 3, 50134, Florence, Italy.

Chiara Donnini (C)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria Careggi, Lg. Brambilla 3, 50134, Florence, Italy.

Federico Meo (F)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria Careggi, Lg. Brambilla 3, 50134, Florence, Italy.

Irene Giacomelli (I)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria Careggi, Lg. Brambilla 3, 50134, Florence, Italy.

Maria Luisa Ralli (ML)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria Careggi, Lg. Brambilla 3, 50134, Florence, Italy.

Alice Sereni (A)

Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy.

Elena Sticchi (E)

Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy.

Michela Zari (M)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria Careggi, Lg. Brambilla 3, 50134, Florence, Italy.

Francesca Caldi (F)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria Careggi, Lg. Brambilla 3, 50134, Florence, Italy.

Irene Tassinari (I)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria Careggi, Lg. Brambilla 3, 50134, Florence, Italy.

Maurizio Zanobetti (M)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria Careggi, Lg. Brambilla 3, 50134, Florence, Italy.

Rossella Marcucci (R)

Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy.

Riccardo Pini (R)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria Careggi, Lg. Brambilla 3, 50134, Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH